

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Maria Frank-Kamenetsky*, Aldo Grefhorst[†], Norma N. Anderson[†], Timothy S. Racie*, Birgit Bramlage[‡], Akin Akinc*, David Butler*, Klaus Charisse*, Robert Dorkin*, Yupeng Fan*, Christina Gamba-Vitalo*, Philipp Hadwiger[‡], Muthusamy Jayaraman*, Matthias John[‡], K. Narayanannair Jayaprakash*, Martin Maier*, Lubomir Nechev*, Kallanthottathil G. Rajeev*, Timothy Read*, Ingo Röhl[‡], Jürgen Soutschek*, Pamela Tan[‡], Jamie Wong*, Gang Wang*, Tracy Zimmermann*, Antonin de Fougerolles*, Hans-Peter Vornlocher[‡], Robert Langer^{§¶}, Daniel G. Anderson[¶], Muthiah Manoharan*, Victor Koteliansky*, Jay D. Horton^{¶||}, and Kevin Fitzgerald*[§]

*Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142; Departments of [†]Molecular Genetics and ^{||}Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390; [‡]Roche Kulmbach GmbH, Fritz-Hornschuch-Strasse 9, 95326 Kulmbach, Germany; and [¶]David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139

Contributed by Robert Langer, June 6, 2008 (sent for review May 7, 2008)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of targeting murine, rat, nonhuman primate (NHP), and human PCSK9. For *in vivo* studies, PCSK9 and control siRNAs were formulated in a lipidoid nanoparticle (LNP). Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50–70%. The reduction in PCSK9 transcript was associated with up to a 60% reduction in plasma cholesterol concentrations. These effects were shown to be mediated by an RNAi mechanism, using 5'-RACE. In transgenic mice expressing human PCSK9, siRNAs silenced the human PCSK9 transcript by >70% and significantly reduced PCSK9 plasma protein levels. In NHP, a single dose of siRNA targeting PCSK9 resulted in a rapid, durable, and reversible lowering of plasma PCSK9, apolipoprotein B, and LDLc, without measurable effects on either HDL cholesterol (HDLc) or triglycerides (TGs). The effects of PCSK9 silencing lasted for 3 weeks after a single bolus *i.v.* administration. These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

plasma PCSK9 | tissue LDLR levels

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the mammalian serine proprotein convertase family that typically functions in the proteolytic processing and maturation of secretory proteins (1, 2). PCSK9 was the first family member to be implicated in a dominantly inherited form of hypercholesterolemia (3). Mechanistic studies addressing the function of PCSK9 in mice and humans have demonstrated that overexpression or gain-of-function mutations in *PCSK9* reduced low density lipoprotein receptor (LDLR) protein levels in liver, which significantly increased circulating plasma cholesterol both in mice and humans (4). Additional studies showed that the deletion of *Pcsk9* in mice resulted in increased LDLR levels, accelerated the clearance of low density lipoprotein cholesterol (LDLc), and reduced circulating cholesterol levels (5). Recently, studies in mice have also shown that lowering PCSK9 transcript levels by antisense oligonucleotides resulted in reduced total cholesterol, LDLc, and HDL cholesterol (HDLc) in blood and increased LDLR levels in liver after 6 weeks of treatment (6). This effect was very similar to that observed in the *Pcsk9*^{-/-} mice

(5). Collectively, these studies have clearly established a role for PCSK9 in cholesterol homeostasis.

Validation of PCSK9 as an attractive therapeutic target for the treatment of hypercholesterolemia has come from genetic studies in humans. Cohen *et al.* (7) first identified loss-of-function mutations in *PCSK9* that lowered plasma LDLc in the Dallas Heart Study. In a larger 15-year prospective study, they demonstrated that nonsense mutations in *PCSK9* reduced LDLc levels by 28% and decreased the frequency of CHD by 88% in African Americans (8). Despite this genetic validation, several physiological aspects of potential PCSK9-modifying agents must be further defined to assess therapeutic potential and benefit. For instance, will the acute lowering of PCSK9 (e.g., over 48–72 h) result in LDLc lowering, and if so, will this reduction be associated with other potentially adverse consequences, such as increased liver lipids? Rodents lack cholesterol ester transferase protein (CETP) and carry the majority of their plasma cholesterol in HDL. Thus, they are not ideal models in which to determine whether PCSK9 silencing will only decrease LDLc and not HDLc. Studies in a more relevant model, such as nonhuman primates (NHPs), are required.

Currently, a number of individuals with hypercholesterolemia are unable to reach target LDLc levels with available therapies. To address the efficacy of inhibiting PCSK9 via an siRNA mechanism, we designed and synthesized several siRNA therapeutic molecules to silence PCSK9 mRNA in mice, rats, NHPs, and humans. These siRNAs were administered by using a lipidoid nanoparticle (LNP) to achieve efficient hepatocyte delivery *in vivo*. This approach enabled us to study the effect of *PCSK9* silencing on the levels of PCSK9 mRNA, plasma PCSK9 protein, hepatic LDLR protein,

Author contributions: M.F.-K., H.-P.V., M. Manoharan, V.K., J.D.H., and K.F. designed the research; M.F.-K., A.G., N.N.A., T.S.R., B.B., M. John, J.W., and K.F. performed the research; A.A., D.B., K.C., R.D., Y.F., P.H., M. Jayaraman, K.N.J., M. Maier, L.N., K.G.R., T.R., I.R., J.S., P.T., G.W., T.Z., A.d.F., R.L., and D.G.A. contributed new reagents/analytical tools; M.F.-K., C.G.-V., J.D.H., and K.F. analyzed the data; and M.F.-K., J.D.H., and K.F. wrote the paper.

Conflict of interest statement: R.L. is a shareholder and member of the Scientific Advisory Board of Alnylam. D.G.A. and J.D.H. are consultants of Alnylam Pharmaceuticals. Alnylam also has a license to certain intellectual property invented at Massachusetts Institute of Technology by Drs. Anderson, Langer, and colleagues. M.F.-K., T.S.R., A.A., D.B., K.C., R.D., Y.F., C.G.-V., M. Jayaraman, K.N.J., M. Maier, L.N., K.G.R., T.R., J.S., J.W., G.W., T.Z., A.d.F., M. Manoharan, V.K., and K.F. are employees of Alnylam Pharmaceuticals. B.B., P.H., M. John, I.R., P.T., and H.-P.V. are employees of Roche Kulmbach.

Freely available online through the PNAS open access option.

[§]To whom correspondence may be addressed. E-mail: kfitzgerald@alnylam.com or rlanger@mit.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0805434105/DCSupplemental.

© 2008 by The National Academy of Sciences of the USA




Fig. 1. Lipidoid formulation and effects of PCSK9 silencing in wild-type mice. (A) Cationic lipidoid component structure of the formulation. (B) Dose-dependent decrease in hepatic PCSK9 mRNA (relative to controls) 2 days after dose ($n = 6$ per group). (C) Liver PCSK9 mRNA and total serum cholesterol levels in mice ($n = 5$ per group) 3 days after a dose of 5 mg/kg LNP-PCS-A2 or PBS. (D) Duration of hepatic PCSK9 transcript silencing in mice ($n = 5$ per group) after a single injection of 5 mg/kg or 7.5 mg/kg LNP-PCS-A2. (B) one-way ANOVA with Student's t test; (C and D) two-way ANOVA with Bonferroni test. (B–D) Each value is the group mean \pm STDEV. Asterisks represent statistical difference between PBS and PCSK9 siRNA treated groups. **, $P \leq 0.01$; ***, $P \leq 0.001$

total serum cholesterol, LDLc, and HDLc concentrations in multiple species. These *in vivo* studies demonstrate that PCSK9 lowering by siRNA has an acute effect on plasma LDLc, but not HDLc, in NHPs. Our data validate PCSK9 as a target for therapeutic intervention by siRNA and provide a strategy for treatment of hypercholesterolemia.

Results

Selection and Formulation of Active siRNA Molecules Targeting PCSK9.

A series of approximately 150 siRNAs were designed to be cross-species reactive through an initial bioinformatics analysis and screened *in vitro* for activity in cultured HepG2 cells. Active molecules PCS-A1, PCS-A2, PCS-B2, and PCS-C2 were chosen for further studies based on their pM IC₅₀ values as measured in primary cynomolgus monkey hepatocytes [supporting information (SI) Table S1].

Certain siRNAs can induce immune responses via interferons and proinflammatory cytokines (9, 10). The siRNAs studied here were designed to avoid immune stimulatory sequence motifs. The siRNAs selected for further study contained two nucleotide 3' overhangs to prevent activation of the RIG-1 pathway (11, 12). Nevertheless, the selected siRNAs were also tested for activation of the immune system in primary human blood monocytes (hPBMCs). Specifically, IFN- α and TNF- α were measured in hPBMCs transfected with each molecule listed in Table S1. The parental compound PCS-A1 was found to induce both IFN- α and TNF- α . However, its chemically modified version, PCS-A2, and chemically modified duplexes PCS-B2 and PCS-C2, were negative for both IFN- α and TNF- α induction in these assays (Table S1 and Fig. S1 for a PCS-A1/PCS-A2 paired example). These results demonstrate that chemical modifications are capable of attenuating both IFN- α and TNF- α responses to siRNA molecules.

LNP is a lipidoid formulation comprised of a novel cationic component 98N₁₂₋₅ (1)·4HCl (Fig. 1A), cholesterol, and a poly(ethylene glycol)-lipid (13). We have shown that LNP-formulated siRNAs that target apoB or Factor VII mediated *in vivo* silencing in liver at doses of 5 mg/kg with minimal toxicity and without perturbation of the endogenous miRNA biogenesis

pathway (12). Here, we use LNP to formulate and test our RNAi therapeutics against PCSK9 in mice, rats, and NHPs.

Silencing of Hepatic PCSK9 mRNA in Rodents Results in Rapid and Reversible Lowering of Serum Cholesterol. *Pcsk9*^{-/-} mice have $\approx 50\%$ reduction in total serum cholesterol concentrations (5). To test whether acute silencing of the PCSK9 transcript by a PCSK9-specific siRNA would result in acutely lower serum cholesterol levels, we formulated a cross-species siRNA molecule PCS-A2 in LNP for study *in vivo*. Various doses of the lipidoid-formulated PCS-A2 (LNP-PCS-A2) were injected via the tail vein into mice and rats.

In mice, livers were harvested to measure PCSK9 mRNA levels and blood was collected for total cholesterol analysis. As shown in Fig. 1B, LNP-PCS-A2 displayed a dose response with maximal PCSK9 mRNA silencing of $\approx 60\text{--}70\%$ at a dose of 5 mg/kg. The decrease of mRNA transcript levels (at the highest dose) translated into $\approx 30\%$ lowering of total plasma cholesterol (Fig. 1C). The reduction in serum cholesterol was similar to that measured in mice heterozygous for a disrupted *Pcsk9* allele (5 and J.D.H., unpublished observations). Moreover, the effect on the PCSK9 transcript persisted for ≈ 20 days, with higher doses displaying greater initial transcript level reduction and subsequently more prolonged effects (Fig. 1D).

Next, we studied rats, which are resistant to cholesterol lowering by high doses of HMG-CoA reductase inhibitors (statins) (14, 15). In rats, LNP-PCS-A2 was dosed 1–5 mg/kg, which resulted in a dose-dependent reduction in the PCSK9 transcript with 50–60% silencing at the highest dose (Fig. 2A). The mRNA silencing was associated with an acute 50–60% decrease of serum total cholesterol (Fig. 2A and B) lasting 10 days, with a gradual return to predose levels by ≈ 3 weeks (Fig. 2B)

Lowering of proteins involved in very-low-density lipoprotein assembly and secretion (microsomal triglyceride transfer protein; MTP or apoB) by genetic deletion, small molecule inhibitors, or siRNA, results in increased liver TGs (16, 17) (T.Z., unpublished data). To determine whether cholesterol lowering via PCSK9 inhibition alters liver lipid content, hepatic cholesterol and TG concentrations in livers of treated and control animals were quantified. As shown in Fig. 2C, there was no




Fig. 2. Hepatic PCSK9 silencing, hepatic TGs, and LDLR levels in rats. (A) LNP-PCS-A2 mediated dose-dependent lowering of hepatic PCSK9 mRNA and total serum cholesterol 3 days after dose ($n = 6$ per group). Each value is the group mean \pm STDEV. One-way ANOVA with Student's t test. Asterisks represent statistical difference between PBS- and PCSK9 siRNA-treated groups *, $P \leq 0.05$; **, $P \leq 0.01$. (B) Total serum cholesterol lowering of LNP-PCS-A2 treated rats ($n = 6$ per group) is maximal ($\approx 60\%$) by 2 days after dose and returns to baseline over ≈ 21 days. PCSK9-treated groups are statistically significant (until approximately day 16) compared with PBS and LNP-Ctrl groups (one-way ANOVA, Student's t test, with P values of ≤ 0.05). (C) Liver TGs and cholesterol contents from treated and control animals (same as in A). There were no significant differences in the liver TGs (ANOVA: $P = 0.824$ for cholesterol content ANOVA on ranks; $P = 0.935$ for LNP-PCS-A2-treated animals vs. the LNP-Ctrl- or PBS-treated control groups for TG levels). (D) Immunoblot of liver extracts from LNP-PCS-A2-, LNP-Ctrl-, and PBS-treated rats (same as in A). Transferrin receptor (TFR) levels were used to normalize for protein loading. (Note that treated animal lane 15 was a noticeable outlier that did not up-regulate LDLR and on close examination also did not lower PCSK9 levels, possibly because of a misinjection). †, relative to PBS.

statistically significant difference in liver TG or cholesterol concentrations among animals administered PCSK9 siRNAs compared with control rats.

The mechanism by which PCSK9 impacts plasma cholesterol levels has been linked to the density of LDLRs on the hepatocyte cell surface (5, 18–20). *Pcsk9*^{-/-} mice have 2- to 3-fold higher levels of liver LDLR protein compared with wild-type mice, and this effect is magnified by statin treatment (5). Similarly, reduction of PCSK9 (using antisense oligos) over a 6-week period in high-fat-fed mice resulted in an up-regulation of LDLR levels (6). To investigate whether regulation of hepatic LDLRs occurred upon siRNA silencing of PCSK9 in rats, liver LDLR levels were quantified by immunoblot analysis after their treatment with 5 mg/kg LNP-PCS-A2. As shown in Fig. 2D, LNP-PCS-A2-treated animals had a significant 3- to 5-fold induction of LDLR levels compared with PBS- or LNP-Ctrl-treated animals. Together, the rodent studies demonstrate that lowering of PCSK9 mRNA levels with siRNAs targeting PCSK9 in the liver results in an acute and durable decrease of serum cholesterol as a result of increased hepatic LDLR expression, and the acute change in LDLR expression is not associated with excess lipid accumulation in the liver.

In Vivo Mechanism of PCSK9 Silencing Is siRNA Mediated. To confirm that the reduction in PCSK9 transcript observed in rodents was because of a siRNA mechanism, liver extracts from either treated or control rats were subjected to rapid amplification of cDNA ends (5'-RACE), a method previously used to demonstrate that siRNA-mediated cleavage occurs (21, 22). 5'-RACE analysis of liver mRNA from animals treated with LNP-PCS-A2 revealed a product of the expected size (Fig. 3). Sequence analysis of cloned PCR products demonstrated that 73 of 84 of these products were derived from the predicted cleavage event at position (*GAGT/TTAT*). No specific bands were amplified in the 5'-RACE experiments from PBS- or LNP-Ctrl-treated animals. These results demonstrate that the effect of LNP-PCS-A2 observed on hepatic PCSK9 mRNA levels is consistent with

cleavage of the PCSK9 transcript via a targeted RNAi-specific mechanism.

Efficacy of siRNA-Mediated Inhibition of Human PCSK9 in Transgenic Mice. Next, we tested the ability of LNP-PCS-A2 and LNP-PCS-C2 (PCS-C2 targets only human and NHP PCSK9 mRNA) (see Table S1) to silence human *PCSK9* *in vivo*. To this end, we used a line of transgenic mice that express human PCSK9 cDNA under the apoE promoter (23). Specific PCR reagents and antibodies were designed that detect human, but not mouse, transcripts and protein, respectively. Cohorts of the humanized transgenic mice were injected with a single 5 mg/kg dose of LNP-PCS-A2 or LNP-PCS-C2, and both livers and blood were collected 72 h later. As shown in Fig. 4A, a single dose of LNP-PCS-A2 or LNP-PCS-C2 was able to decrease the human PCSK9 transcript levels by $>70\%$, and this resulted in >500 -fold reduction in the levels of circulating human PCSK9 protein as measured by ELISA (Fig. 4B). These results demonstrated that both siRNAs were capable of silencing the human transcript and, subsequently, reducing the amount of circulating plasma human




Fig. 3. siRNA-mediated cleavage of PCSK9 mRNA in rats (5'-RACE). Rats ($n = 4$ per group) were administered with 4 mg/kg LNP-PCS-A2, LNP-Ctrl, or PBS and killed 4 days later. 5'-RACE detects the predicted mRNA cleavage product in LNP-PCS-A2- and not in LNP-Ctrl- or PBS-treated animals. Eighty-seven percent of clones from the circled bands mapped to the predicted siRNA specific cleavage site.




Fig. 4. Silencing of human PCSK9 mRNA and protein reduction in PCSK9 humanized mice. (A) Transgenic mice ($n = 4$ per group) expressing the human PCSK9 full-length cDNA under the apoE promoter were dosed with LNP-PCS-A2 and LNP-PCS-C2, and LNP-Ctrl or PBS. Both LNP-PCS-C2 and LNP-PCS-A2 significantly lowered the human transcript as measured by quantitative PCR 3 days after dose. Each value is the group mean \pm STDEV. (One-way ANOVA, Student's t test, $P \leq 0.001$ between PBS- and PCSK9 siRNA-treated groups). (B) Circulating human PCSK9 protein levels were reduced in treated vs. control transgenic mice ($n = 4$ per group) as measured by ELISA. Each value represents group mean \pm STDEV. All time points for the PCSK9 siRNA treated groups are statistically significant compared with PBS (Two-way ANOVA, Bonferroni test, $P \leq 0.01$).

PCSK9 protein. Interestingly, the human/NHP selective PCS-C2 showed efficacy comparable to that of the cross-species PCS-A2. This result validates an approach where cross-species active siRNAs can be used in the development of RNAi therapeutic drugs.

RNAi Silencing of PCSK9 Acutely Reduces PCSK9 Protein and Plasma LDLc, but Not Plasma HDLc, in NHPs. The results above demonstrated that siRNAs targeting PCSK9 acutely lower both plasma PCSK9 protein and total cholesterol levels with an effect that lasts ≈ 3 weeks after a single dose in mice and rats. To extend these findings to a more relevant species with lipoprotein profiles that more closely resemble humans, we carried out similar experiments in cynomolgus monkeys.

Animals were randomized based on day 3 LDLc levels. On the day of dosing (designated day 1), PBS and 1 mg/kg or 5 mg/kg of LNP-PCS-A2, -B2, and -Ctrl were administered as a single infusion over 30 min. As the experiment progressed, it became apparent that the 1 mg/kg dose was not efficacious in reducing plasma LDLc (Fig. S2). We therefore dosed the PBS group animals on day 14 with 5 mg/kg LNP-Ctrl so that they could serve as controls for animals that received the 5 mg/kg LNP-PCS-A2 and LNP-PCS-B2. The PBS- and LNP-Ctrl-treated animals behaved similarly for all measured endpoints (data not shown and Figs. S2 and S3A).

As shown in Fig. 5A, a single dose of 5 mg/kg LNP-PCS-A2 or LNP-PCS-B2 resulted in a statistically significant reduction of LDLc beginning at day 3 after the dose that returned to baseline over ≈ 14 days (for LNP-PCS-A2) and ≈ 21 days (LNP-PCS-B2). This effect was not observed in the PBS group, the LNP-Ctrl group, or the 1 mg/kg treatment groups (Fig. 5A and Figs. S2 and S3A). LNP-PCS-B2 resulted in an average LDLc lowering of 56%, 72 h after the dose, with one of the four animals achieving nearly a 70% reduction in plasma LDLc compared with predose levels (see Fig. 5A and Fig. S3A). As expected, the lowering of LDLc in the treated animals correlated with a trend toward lower circulating apoB levels as measured by serum ELISA (Fig. S3B).

Neither LNP-PCS-A2 nor LNP-PCS-B2 treatments resulted in a lowering of HDLc in this study. In fact, both siRNAs resulted (on average) in a trend toward a decreased total cholesterol/HDLc ratio (Fig. 5B). In addition, plasma TG levels were not




Fig. 5. Pharmacology of PCSK9 silencing in NHPs. (A) Direct LDLc measurements of serum from cynomolgus monkeys treated with 5 mg/kg LNP-PCS-A2 ($n = 5$ per group), LNP-PCS-B2 ($n = 4$ per group), or PBS ($n = 3$ per group). (B) Total cholesterol/HDL ratios as measured in the samples described in A. (C) Plasma samples from the treatment groups in A were analyzed for their levels of PCSK9 protein by ELISA. Values for LDLc, Tc/HDLc, and PCSK9 concentrations were graphed as a ratio of the average values of after dose compared with predose values within an animal. Those values were then combined into group averages. (A–C) LNP-Ctrl behaved similarly on d4 and d7 as PBS (data not shown). PBS values are the mean of the groups \pm STDEV averaged over days 3–14. Each value represents the mean of the group \pm STDEV. Two-way ANOVA with Bonferroni test was used. Asterisks represent statistical difference between PBS- and PCSK9 siRNA-treated groups. **, $P \leq 0.01$; ***, $P \leq 0.001$.

altered (data not shown). ALT and AST levels were not significantly impacted (<3 -fold induction over baseline in the same animal) with the exception of animal 6002, which had a 4- to 5-fold increased ALT and 4- to 9-fold increased AST (Table S2). We note that animals in this study were a mixture of naïve and nonnaïve animals (one naïve per group), with several animals having somewhat elevated ALT or AST at baseline (animal 6002 was nonnaïve). However, the cholesterol effects observed were independent of these measures as animals with no apparent increases in liver enzymes had similar LDLc reductions as animal 6002 (Table S2 and Fig. S3A).

Inasmuch as these experiments were nonterminal, we were unable to measure the reduction of transcript levels in the liver. As a surrogate for effects of siRNA treatment on PCSK9 transcript silencing, we measured plasma PCSK9 protein levels in both treated and control NHPs by ELISA. As shown in Fig. 5C, compared with predose concentrations, both LNP-PCS-A2 and LNP-PCS-B2 treatments significantly reduced plasma PCSK9 concentrations. One caveat to measuring circulating PCSK9 levels in the context of LNP01 formulated siRNAs is that the delivery and silencing of PCSK9 is greatest in the liver as opposed to other tissues, such as the intestine, where PCSK9 is also expressed. It therefore remains possible that our measurements are an underestimate of liver PCSK9 protein lowering.

PCSK9 ELISA. A quantitative assay for cynomolgus monkeys PCSK9 concentration in blood was carried out by using a sandwich ELISA method as previously reported for humans with minor modifications as described (see *SI Text*).

Other Materials and Methods. Detailed descriptions of experimental protocols and reagents are described in *SI Text*.

ACKNOWLEDGMENTS. We thank John Maraganore for helpful comments and guidance; Maryellen Duckman and Nancy Heard for graphics assistance;

Thuchien Thi Nguyen, Sara Nochur, and Akshay Vaishnav for helpful advice and comments; Kerstin Jahn-Hoffmann, Stephan Seiffert, Garry Lavine, Sergey Shulga-Morskoy, Kathy Mills, Christine Thein, Nadine Linke, Andre Wetzel, Denise Müller, Astrid Degenhard, Mike Power, Abigail Capobianco, Harald Schübel, Günther Ott, Doris Trapper, Uschi Bauernfeind, Claudia Woppmann, Y.K. Ho, Lauren Koob, Tuyet Dang, and Judy Sanche for assistance and helpful suggestions. This work was supported in part by grants from the Perot Family Foundation, National Institutes of Health Grants HL-20948 and EB00244, and the Royal Netherlands Academy of Arts and Science Ter Meulen Fund.

1. Seidah NG, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. *Proc Natl Acad Sci USA* 100:928–933.
2. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ (2005) Proprotein convertases: “Master switches” in the regulation of tumor growth and progression. *Mol Carcinog* 44:151–161.
3. Abifadel M, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet* 34:154–156.
4. Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: Its role in LDL metabolism. *Trends Biochem Sci* 32:71–77.
5. Rashid S, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. *Proc Natl Acad Sci USA* 102:5374–5379.
6. Graham MJ, et al. (2007) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. *J Lipid Res* 48:763–767.
7. Cohen J, et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat Genet* 37:161–165.
8. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 354:1264–1272.
9. Hornung V, et al. (2005) Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat Med* 11:263–270.
10. Schlee M, Hornung V, Hartmann G (2006) siRNA and isRNA: Two edges of one sword. *Mol Ther* 14:463–470.
11. Yoneyama M, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5:730–737.
12. John M, et al. (2007) Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. *Nature* 449:745–747.
13. Akinc A, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat Biotechnol* 26:561–569.
14. Kasim SE, Elovson J, Khilnani S, Almarino RU, Jen KL (1993) Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. *Atherosclerosis* 104:147–152.
15. Krause BR, Newton RS (1995) Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rats correlates with efficacy in LDL animal models. *Atherosclerosis* 117:237–244.
16. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D (2003) Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice. *Hepatology* 38:133–140.
17. Ibdah JA, et al. (2005) Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. *Gastroenterology* 128:1381–1390.
18. Benjannet S, et al. (2004) NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J Biol Chem* 279:48865–48875.
19. Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proc Natl Acad Sci USA* 101:7100–7105.
20. Park SW, Moon YA, Horton JD (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. *J Biol Chem* 279:50630–50638.
21. Soutschek J, et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* 432:173–178.
22. Zimmermann TS, et al. (2006) RNAi-mediated gene silencing in non-human primates. *Nature* 441:111–114.
23. Lagace TA, et al. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. *J Clin Invest* 116:2995–3005.
24. Zhao Z, et al. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am J Hum Genet* 79:514–523.
25. Athyros VG, et al. (2008) Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. *Am J Cardiol* 101:483–485.
26. Rouleau J (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: Results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. *Am J Med* 118 Suppl 12A:28–35.
27. Schwartz GG, et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. *Jama* 285:1711–1718.
28. Greffhorst A, McNutt MC, Lagace TA, Horton JD (2008) Plasma PCSK9 preferentially reduces liver LDL receptors in mice. *J Lipid Res* 49:1303–1311.